Structure-activity studies related to ABT-594, a potent nonopioid analgesic agent: effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice.

[1]  S. Arneric,et al.  Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice. , 1998, European journal of pharmacology.

[2]  D. Donnelly-roberts,et al.  Synthesis and structure-activity relationships of pyridine-modified analogs of 3-[2-((S)-pyrrolidinyl)methoxy]pyridine, A-84543, a potent nicotinic acetylcholine receptor agonist. , 1998, Bioorganic & medicinal chemistry letters.

[3]  D. Donnelly-roberts,et al.  Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. , 1998, Journal of medicinal chemistry.

[4]  D. Donnelly-roberts,et al.  Broad-spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. , 1998, Science.

[5]  J. Wroblewski,et al.  Synthesis and biology of the rigidified glutamate analogue, trans-2-carboxyazetidine-3-acetic acid (t-CAA) , 1996 .

[6]  D. Donnelly-roberts,et al.  Novel 3-Pyridyl ethers with subnanomolar affinity for central neuronal nicotinic acetylcholine receptors. , 1996, Journal of medicinal chemistry.

[7]  A. Maycock,et al.  Orally active beta-lactam inhibitors of human leukocyte elastase. 3. Stereospecific synthesis and structure-activity relationships for 3,3-dialkylazetidin-2-ones. , 1995, Journal of medicinal chemistry.

[8]  A. Abbott.  Rome "could host European mouse laboratory" , 1994, Nature.

[9]  R. Ronald,et al.  Regioselective metalation reactions of some substituted (methoxymethoxy)arenes , 1982 .